Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomics-guided targeted or immunotherapy vs platinum chemotherapy in cancer of unknown primary
jRCT2071200082Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised trial of alectinib, atezolizumab, bevacizumab, cobimetinib, entrectinib and 11 more in cancer of unknown primary (CUP) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: progression-free survival. Started Jun 2020; status: completed.
02
Drugs
alectinibatezolizumabbevacizumabcobimetinibentrectinib
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on jRCT2071200082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200082.